India's withdrawal of an AIDS treatment drug patent protection
http://china.ibtimes.com 2009 Nian 09 Yue 03 Ri 19:07 Source: International Financial Times


September 3 Delhi, India, Patent Office has accepted the message of generic drug maker Cipla, India's request, refused to tenofovir (tenofovir) to implement patent protection in developing countries AIDS (HIV) patients will have greater opportunities to acquire kinds of life-saving medicines.

According to British "Financial Times" reported that the brand name for tenofovir tenofovir (Viread), is a widely used AIDS treatment drugs, is a US-based biotechnology company Gilead successfully developed.

Revocation of the decision of the drug patent protection may be a parallel patent application of the challenge, but it relaxed in India's booming low-cost generic drugs cheaper manufactured and sold in emerging markets such drug restrictions. The decision also indicates that the future may be more intense competition, price cut also may be greater.

Gilead is a blow for the company's attempt in the international market to strengthen drug control. A number of local companies in India will also be hit, Gilead has worked with these companies, together with reduced sales to the poorest countries the drug prices, but retained its own in the middle-income market, the exclusive marketing rights.

India in 2005 introduced an even more stringent drug patent protection regulations, in order to make these provisions have been used, Gilead has licensed local producers manufacture tenofovir, but asking them to pay royalties, and are not allowed to bring drugs to sell to Brazil China and other middle-income countries.

Cipla refused to accept the above conditions in favor of the drug at the same time in the production of its patent challenge. Cipla chairman Hamierde (Yusuf Hamied), said: "I am very happy. This is one of the world's leading anti-AIDS drugs, and now I can say without hesitation to promote it."